Clinical Trial: A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)
Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Systemic Lupus Erythematosus (SL
Brief Summary: The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory Systemic Lupus Erythematosus (SLE).
Detailed Summary:
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Dates:
Date Received: May 11, 2023
Date Started: September 13, 2023
Date Completion: September 13, 2023
Last Updated: January 02, 2024
Last Verified: January 01, 2024